You are now leaving the ViiV Healthcare website and being re-directed to an external website
Explore ViiV Healthcare
Read the report, available now in English and Spanish
As the only company solely focused on HIV, we go beyond developing new medicines. We take a holistic approach to HIV by developing and supporting sustainable community programs — with and for the HIV community.
ViiV Healthcare has a long-standing commitment to activities that deliver education, treatment and prevention and access to care through on-the-ground programs.
The voice of the HIV community informs everything we do to improve the lives and health outcomes of all people living with HIV.
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
Read all news
We must stand together to reduce disparities in communities disproportionately impacted by HIV, with the goal of leaving no person living with HIV behind.
Read how to report a side effect.
Website images are not intended to imply that the models pictured have HIV.
©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.
Connect with us